Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1525454 | 1.00 | ALOX15 (0.74) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| SCHEMBL8089487 | 1.00 | ALOX15 (0.74) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| SCHEMBL819207 | 0.97 | — | — | |
| SCHEMBL517338 | 0.97 | — | — | |
| SCHEMBL517340 | 0.97 | — | — | |
| SCHEMBL517339 | 0.97 | — | — | |
| SCHEMBL29394097 | 0.94 | ALOX15 (0.74) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| Diethylamine SCHEMBL1524932 | 0.85 | ALOX15 (1.00) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| Diethylamine SCHEMBL447262 | 0.85 | ALOX15 (1.00) | ALOX15CYP3A4KDM4EMEN1TSHR | |
| Diethylamine SCHEMBL1524933 | 0.85 | ALOX15 (1.00) | ALOX15CYP3A4KDM4EMEN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3266463-B1 | HEMOGLOBIN COMPOSITIONS | PROLONG PHARMACEUTICALS LLC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSTY | 2022-03-24 | — | — | US | disclosed |
| US-11148999-B2 | Nitric oxide donors | MedChem Partners, LLC (US) | 2021-10-19 | — | — | US | disclosed |
| US-10780148-B2 | Hemoglobin compositions | Prolong Pharmaceuticals, LLC (US) | 2020-09-22 | — | — | US | disclosed |
| US-10772937-B2 | Hemoglobin compositions | Prolong Pharmaceuticals, LLC (US) | 2020-09-15 | — | — | US | disclosed |
| WO-2020150698-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20190345099-A1 | NITRIC OXIDE DONORS | MEDCHEM PARTNERS, LLC. | 2019-11-14 | — | — | US | disclosed |
| US-10172949-B2 | Hemoglobin compositions | Prolong Pharmaceuticals, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-10172950-B2 | Hemoglobin compositions | Prolong Pharmaceuticals, LLC (US) | 2019-01-08 | — | — | US | disclosed |
| US-20190000929-A1 | Hemoglobin Compositions | PROLONG PHARMACEUTICALS LLC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-03-18 | — | — | US | disclosed |
| WO-2004012686-A2 | NITROSATED AND/OR NITROSYLATED URSODEOXYCHOLIC ACID COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| WO-2004012659-A2 | NITROSATED PROTON PUMP INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-12 | — | — | WO | disclosed |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NITROMED, INC. (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2004010945-A2 | CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NITROMED, INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2004004648-A2 | NITROSATED NONSTEROIDAL ANTIINFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004002420-A2 | OXIME AND/OR HYDRAZONE CONTAINING NITROSATED AND/OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2004-01-08 | — | — | WO | disclosed |
| US-20040006133-A1 | Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | NITROMED, INC. | 2004-01-08 | — | — | US | disclosed |
| WO-2003103602-A2 | NITROSATED AND/OR NITROSYLATED CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053985-A1 | Cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, PTGIS, PTGES2 | ALOX15 32/4885CYP3A4 214/4885KDM4E 3402/4885 |
| US-20040024057-A1 | Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications | NOS2, NOS1, NOS3 | ALOX15 32/4885CYP3A4 268/4885KDM4E 4225/4885 |
| US-20190345099-A1 | NITRIC OXIDE DONORS | NOS2, NOS1, NOS3 | ALOX15 107/4885CYP3A4 100/4885KDM4E 1758/4885 |
| US-11148999-B2 | Nitric oxide donors | NOS2, NOS1, NOS3 | ALOX15 107/4885CYP3A4 100/4885KDM4E 1758/4885 |
| US-20220087970-A1 | PREVENTION OF ANESTHETIC-INDUCED NEUROCOGNITIVE DYSFUNCTION | PYGB, PRKG1, ACHE | ALOX15 858/4885CYP3A4 2031/4885KDM4E 3051/4885 |
| US-20040006133-A1 | Oxime and/or hydrozone containing nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use | PTGS2, HMOX1, NOS2 | ALOX15 57/4885CYP3A4 252/4885KDM4E 3129/4885 |
| US-20040024014-A1 | Nitrosated proton pump inhibitors, compositions and methods of use | NOS1, PTGS1, NOS2 | ALOX15 81/4885CYP3A4 378/4885KDM4E 3767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.